Silymarin suppresses the PGE2-induced cell migration through inhibition of EP2 activation; G protein-dependent PKA-CREB and G protein-independent Src-STAT3 signal pathways

Molecular Carcinogenesis

Volumn 54, Issue 3, 2015, Pages 216-228

  Woo, Seon Min ^a   Min, Kyoung Jin ^a   Chae, In Gyeong ^b   Chun, Kyung Soo ^b   Kwon, Taeg Kyu ^a  

^a Keimyung University School of Medicine   (South Korea)

^b Keimyung University   (South Korea)

Author keywords

EP2; Migration; PGE2; Renal carcinoma; Silymarin

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROSTAGLANDIN E RECEPTOR 2; PROSTAGLANDIN E2; SILYMARIN; STAT3 PROTEIN; 1,3 BENZODIOXOLE DERIVATIVE; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; ANTIOXIDANT; BUTAPROST; CRE RECOMBINASE; CREB1 PROTEIN, HUMAN; ENZYME INHIBITOR; INTEGRASE; PROSTAGLANDIN E1; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROTEIN TYROSINE KINASE; PTGER2 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; SARACATINIB; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN; XANTHONE DERIVATIVE;

ARTICLE; CANCER CELL; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WOUND HEALING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL MOTION; DRUG EFFECTS; ENZYME ACTIVATION; GENETICS; HCT116 CELL LINE; HT 29 CELL LINE; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; TUMOR CELL LINE;

ALPROSTADIL; ANTIOXIDANTS; BENZODIOXOLES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CELL MOVEMENT; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DINOPROSTONE; DOWN-REGULATION; ENZYME ACTIVATION; ENZYME INHIBITORS; GTP-BINDING PROTEINS; HCT116 CELLS; HT29 CELLS; HUMANS; INTEGRASES; KIDNEY NEOPLASMS; PHOSPHORYLATION; PROSTAGLANDIN ANTAGONISTS; QUINAZOLINES; RECEPTORS, PROSTAGLANDIN E, EP2 SUBTYPE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SILYMARIN; SRC-FAMILY KINASES; STAT3 TRANSCRIPTION FACTOR; WOUND HEALING; XANTHONES;

EID: 84926115959     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.22092     Document Type: Article

References (45)

1. Greenhough A, Smartt HJ, Moore AE, et al. The COX-2/PGE2 pathway: Key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009; 30:377-386.
2. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003; 74:143-153.
3. Hull MA, Ko SC, Hawcroft G. Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer? Mol Cancer Ther 2004; 3:1031-1039.
4. Buchanan FG, Gorden DL, Matta P, Shi Q, Matrisian LM, DuBois RN. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci USA 2006; 103:1492-1497.
5. Chun KS, Akunda JK, Langenbach R. Cyclooxygenase-2 inhibits UVB-induced apoptosis in mouse skin by activating the prostaglandin E2 receptors, EP2 and EP4. Cancer Res 2007; 67:2015-2021.
6. Chun KS, Lao HC, Trempus CS, Okada M, Langenbach R. The prostaglandin receptor EP2 activates multiple signaling pathways and beta-arrestin1 complex formation during mouse skin papilloma development. Carcinogenesis 2009; 30:1620-1627.
7. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005; 65:9304-9311.
8. Sung YM, He G, Hwang DH, Fischer SM. Overexpression of the prostaglandin E2 receptor EP2 results in enhanced skin tumor development. Oncogene 2006; 25:5507-5516.
9. Sheng H, Shao J, Washington MK, DuBois RN. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J Biol Chem 2001; 276:18075-18081.
10. Timoshenko AV, Xu G, Chakrabarti S, Lala PK, Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 2003; 289:265-274.
11. Timoshenko AV, Lala PK, Chakraborty C. PGE2-mediated upregulation of iNOS in murine breast cancer cells through the activation of EP4 receptors. Int J Cancer 2004; 108:384-389.
12. Wu J, Zhang Y, Frilot N, Kim JI, Kim WJ, Daaka Y. Prostaglandin E2 regulates renal cell carcinoma invasion through the EP4 receptor-Rap GTPase signal transduction pathway. J Biol Chem 2011; 286:33954-33962.
13. Luttrell DK, Luttrell LM. Not so strange bedfellows: G-protein-coupled receptors and Src family kinases. Oncogene 2004; 23:7969-7978.
14. Chun KS, Lao HC, Langenbach R. The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways. J Biol Chem 2010; 285:39672-39681.
15. Kim JI, Lakshmikanthan V, Frilot N, Daaka Y. Prostaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome. Mol Cancer Res 2010; 8:569-577.
16. Wagner H, Horhammer L, Munster R. On the chemistry of silymarin (silybin), the active principle of the fruits from Silybum marianum (L.) Gaertn. (Carduus marianus L.). Arzneimittelforschung 1968; 18:688-696.
17. Katiyar SK. Silymarin and skin cancer prevention: anti-inflammatory, antioxidant and immunomodulatory effects (Review). Int J Oncol 2005; 26:169-176.
18. Deep G, Agarwal R. Chemopreventive efficacy of silymarin in skin and prostate cancer. Integr Cancer Ther 2007; 6:130-145.
19. Ramasamy K, Agarwal R. Multitargeted therapy of cancer by silymarin. Cancer Lett 2008; 269:352-362.
20. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18:581-592.
21. Gore ME, Larkin JM. Challenges and opportunities for converting renal cell carcinoma into a chronic disease with targeted therapies. Br J Cancer 2011; 104:399-406.
22. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30:843-852.
23. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353:2477-2490.
24. Howe AK, Baldor LC, Hogan BP. Spatial regulation of the cAMP-dependent protein kinase during chemotactic cell migration. Proc Natl Acad Sci USA 2005; 102:14320-14325.
25. Iwanaga K, Okada M, Murata T, Hori M, Ozaki H. Prostaglandin E2 promotes wound-induced migration of intestinal subepithelial myofibroblasts via EP2, EP3, and EP4 prostanoid receptor activation. J Pharmacol Exp Ther 2012; 340:604-611.
26. Ansari KM, Sung YM, He G, Fischer SM. Prostaglandin receptor EP2 is responsible for cyclooxygenase-2 induction by prostaglandin E2 in mouse skin. Carcinogenesis 2007; 28:2063-2068.
27. Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 2001; 15:465-489.
28. Tyagi A, Agarwal C, Harrison G, Glode LM, Agarwal R. Silibinin causes cell cycle arrest and apoptosis in human bladder transitional cell carcinoma cells by regulating CDKI-CDK-cyclin cascade, and caspase 3 and PARP cleavages. Carcinogenesis 2004; 25:1711-1720.
29. Yanaida Y, Kohno H, Yoshida K, et al. Dietary silymarin suppresses 4-nitroquinoline 1-oxide-induced tongue carcinogenesis in male F344 rats. Carcinogenesis 2002; 23:787-794.
30. Bhatia N, Zhao J, Wolf DM, Agarwal R. Inhibition of human carcinoma cell growth and DNA synthesis by silibinin, an active constituent of milk thistle: comparison with silymarin. Cancer Lett 1999; 147:77-84.
31. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in a mouse skin model. J Natl Cancer Inst 1997; 89:556-566.
32. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant, silymarin, in human breast cancer cells MDA-MB 468: induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin-dependent kinases and associated cyclins. Clin Cancer Res 1998; 4:1055-1064.
33. Gallo D, Giacomelli S, Ferlini C, et al. Antitumour activity of the silybin-phosphatidylcholine complex, IdB 1016, against human ovarian cancer. Eur J Cancer 2003; 39:2403-2410.
34. Singh RP, Deep G, Chittezhath M, et al. Effect of silibinin on the growth and progression of primary lung tumors in mice. J Natl Cancer Inst 2006; 98:846-855.
35. Menter DG, Schilsky RL, DuBois RN. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res 2010; 16:1384-1390.
36. Dannenberg AJ, Howe LR. The role of COX-2 in breast and cervical cancer. Prog Exp Tumor Res 2003; 37:90-106.
37. Dohadwala M, Batra RK, Luo J, et al. Autocrine/paracrine prostaglandin E2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J Biol Chem 2002; 277:50828-50833.
38. Rozic JG, Chakraborty C, Lala PK. Cyclooxygenase inhibitors retard murine mammary tumor progression by reducing tumor cell migration, invasiveness and angiogenesis. Int J Cancer 2001; 93:497-506.
39. Huang HF, Shu P, Murphy TF, Aisner S, Fitzhugh V, Jordan ML. Significance of divergent expression of prostaglandin EP4 and EP3 receptors in human prostate cancer. Mol Cancer Res 2013; 427-439.
40. Kaur M, Agarwal R. Silymarin and epithelial cancer chemoprevention: how close we are to bedside? Toxicol Appl Pharmacol 2007; 224:350-359.
41. Singh T, Katiyar SK. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS ONE 2011; 6:e25224.
42. Jin J, Chang Y, Wei W, et al. Prostanoid EP1 receptor as the target of (-)-epigallocatechin-3-gallate in suppressing hepatocellular carcinoma cells in vitro. Acta Pharmacol Sin 2012; 33:701-709.
43. Singh T, Vaid M, Katiyar N, Sharma S, Katiyar SK. Berberine, an isoquinoline alkaloid, inhibits melanoma cancer cell migration by reducing the expressions of cyclooxygenase-2, prostaglandin E(2) and prostaglandin E(2) receptors. Carcinogenesis 2011; 32:86-92.
44. Ma X, Kundu N, Collin PD, Goloubeva O, Fulton AM. Frondoside A inhibits breast cancer metastasis and antagonizes prostaglandin E receptors EP4 and EP2. Breast Cancer Res Treat 2012; 132:1001-1008.
45. Rundhaug JE, Simper MS, Surh I, Fischer SM. The role of the EP receptors for prostaglandin E2 in skin and skin cancer. Cancer Metastasis Rev 2011; 30:465-480.